About Transgene Biotek
Transgene Biotek is a company based in Mardi (India) founded in 1990. Transgene Biotek offers products and services including Oncology Therapies, Auto-Immunity Solutions, Biogenerics Portfolio, and Drug Delivery Systems. Transgene Biotek operates in a competitive market with competitors including Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
- Headquarter Mardi, India
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Transgene Biotek Limited.
-
Annual Revenue
$30.55 K (USD)10.98as on Mar 31, 2025
-
Net Profit
-$79.13 K (USD)-3.14as on Mar 31, 2025
-
EBITDA
-$131.45 K (USD)-82.13as on Mar 31, 2025
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Transgene Biotek
Transgene Biotek is a publicly listed company on the BSE with ticker symbol TRABI in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Transgene Biotek
Transgene Biotek offers a comprehensive portfolio of products and services, including Oncology Therapies, Auto-Immunity Solutions, Biogenerics Portfolio, and Drug Delivery Systems.
Develops treatments for cancer through research platforms
Creates therapies for immune disorders via biogenerics
Provides generic biologics for various medical applications
Innovates methods for effective drug administration
Funding Insights of Transgene Biotek
Detailed funding history for Transgene Biotek
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Transgene Biotek
Investment portfolio details for Transgene Biotek
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Transgene Biotek
Detailed financials for Transgene Biotek
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Transgene Biotek Comparisons
Peer comparison for Transgene Biotek
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Transgene Biotek
Transgene Biotek operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
Detailed competitors of Transgene Biotek
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Transgene Biotek
Complete news archive for Transgene Biotek
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Transgene Biotek
Transgene Biotek was founded in 1990.
Transgene Biotek is headquartered in Mardi, India. It is registered at Mardi, Himachal Pradesh, India.
Annual revenue of Transgene Biotek is $30.55K as on Mar 31, 2025.
Founded in 1990 and based in Mardi, India, focus is placed on biotechnology within the oncology sector. RNAi and siRNA technologies, along with humanized monoclonal antibodies, are advanced for cancer treatments. An HIV vaccine and a multiple sclerosis drug are being developed using B-cell targeting methods. Oral formulations of insulin, monoclonal antibodies, and HIV therapies are created through the TRABI platform.
Transgene Biotek's top competitors include Jazz Pharmaceuticals, Spark Therapeutics and BridgeBio.
Transgene Biotek offers Oncology Therapies, Auto-Immunity Solutions, Biogenerics Portfolio, and Drug Delivery Systems.
Yes, Transgene Biotek is publicly traded on BSE under the ticker symbol TRABI.
The ticker symbol of Transgene Biotek is TRABI on BSE.